Overview

Detailed Summary

Ganga Pharmaceuticals Ltd manufactures and trades ayurvedic pharmaceuticals, focusing on traditional medicine with a modern approach.
Established in 1994, the company took over an existing ayurvedic business in 1995, signifying a strong foundation in traditional medicine.
The company has a global presence, exporting its products to countries in the Middle East and Europe, indicating a robust international market penetration.
It has invested in expanding manufacturing capabilities, emphasizing a commitment to innovation and meeting increasing demand.
Despite its extensive history, the absence of recent strategic updates raises questions about its current competitive positioning.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Formulations
Market Cap: 7 Cr
Volatility: High Risk
P/E Ratio: 100.0
Industry P/E: 43.5
PEG Ratio: 3.6
P/B Ratio: 0.9
52W High: 14.80
52W Low: 9.25

Sales CAGR

1Y: -3.65%
3Y: 1.95%
5Y: -3.05%
10Y: -0.26%

Profit CAGR

1Y: 60.00%
3Y: 27.77%
5Y: -15.98%
10Y: 5.53%

ROE

TTM: 0.96%
3Y: 0.84%
5Y: 0.73%
10Y: 1.47%

ROCE

TTM: 2.20%
3Y: 3.67%
5Y: 3.74%
10Y: 5.53%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
MEDIORG	21.85	26 Cr	5.97	0.87	0.00	14.02	13.68	7.49
ZENITHHE	3.13	17 Cr	34.78	2.21	0.00	-0.79	1.96	4.20
DESHRAK	23.16	13 Cr	20.97	1.05	0.00	5.08	7.80	3.24
UNJHAFOR	20.08	9 Cr	8.54	2.07	0.00	23.59	26.37	16.12
GANGAPHARM	12.00	7 Cr	100.00	0.89	0.00	0.96	2.20	0.79
COLINZ	45.30	6 Cr	23.11	0.66	0.00	4.69	5.88	4.04

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Standalone Quarterly Results (in ₹ Crores)

Total Figures

QoQ Changes

Total Figures

	Sep 2024
Sales	1.31
Expenses	1.43
Operating Profit	-0.12
OPM %	-9.16
Other Income	0.29
Interest	0.09
Depreciation	0.02
Profit Before Tax	0.07
Tax %	57.14
Net Profit	0.02
EPS in Rs	0.04

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	2.70	3.01	3.05	3.36	3.08	2.37	2.49	2.59	2.74	2.64
Expenses	2.33	2.70	2.73	2.94	2.69	2.34	2.45	2.58	2.68	2.75
Operating Profit	0.37	0.31	0.32	0.42	0.39	0.03	0.04	0.00	0.06	-0.12
OPM %	13.87	10.23	10.53	12.45	12.55	1.31	1.69	0.18	2.11	-4.41
Other Income	0.14	0.16	0.15	0.14	0.17	0.25	0.26	0.30	0.24	0.44
Interest	0.33	0.32	0.28	0.25	0.24	0.19	0.19	0.19	0.18	0.18
Depreciation	0.04	0.04	0.06	0.05	0.05	0.05	0.05	0.06	0.05	0.05
Profit Before Tax	0.07	0.11	0.13	0.26	0.26	0.04	0.05	0.05	0.06	0.09
Tax %	30.59	29.87	25.75	27.61	26.00	45.58	26.00	26.00	26.33	16.55
Net Profit	0.05	0.07	0.09	0.19	0.19	0.02	0.04	0.04	0.05	0.08
EPS in Rs	—	—	—	—	—	—	—	—	—	—
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	4.06	4.06	4.06	4.06	4.06	4.06	4.06	4.06	4.84	4.84
Reserves	0.74	0.81	0.91	1.09	1.29	1.31	1.35	1.39	2.22	2.29
Borrowings	2.19	2.14	2.05	1.87	1.45	1.56	1.93	1.83	1.36	1.42
Other Liabilities	0.34	0.60	1.22	0.73	0.76	0.73	0.66	0.71	0.24	0.42
Total Liabilities	7.33	7.61	8.23	7.76	7.57	7.66	8.00	7.98	8.65	8.97
Fixed Assets	0.62	0.62	0.82	0.80	0.76	0.72	0.68	0.64	0.61	0.66
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.50	0.00	0.00	0.09	0.09	0.09	0.09	0.09	0.09	0.00
Other Assets	6.21	6.99	7.41	6.87	6.72	6.85	7.23	7.26	7.95	8.31
Total Assets	7.33	7.61	8.23	7.76	7.57	7.66	8.00	7.98	8.65	8.97

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-1.05	0.05	0.24	0.11	-0.31	-0.18	-0.21	-0.04	-1.26	-0.58
Cash from Investing Activity	-0.83	0.62	-0.14	0.28	0.37	0.28	0.19	0.49	0.13	1.18
Cash from Financing Activity	1.90	-0.33	-0.36	-0.45	-0.29	-0.10	0.03	-0.44	1.14	-0.33
Net Cash Flow	0.02	0.33	-0.26	-0.05	-0.22	0.00	0.01	0.01	0.00	0.27

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Sep 2024	Mar 2025	Jun 2025	Jul 2025	Sep 2025
Promoters	66.71%	66.71%	66.71%	66.71%	66.71%	56.02%	56.02%	56.02%	56.02%	50.91%	50.91%	50.91%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	33.29%	33.29%	33.29%	33.29%	33.29%	43.98%	43.98%	43.98%	43.98%	49.09%	49.09%	49.09%
Total Shareholders	356	356	355	356	359	362	363	365	368	367	367	366

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY24

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Ganga Pharmaceuticals Ltd

Ganga Pharmaceuticals Ltd (GANGAPHARM) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ganga Pharmaceuticals Ltd manufactures and trades ayurvedic pharmaceuticals, focusing on traditional medicine with a modern approach. Established in 1994, the company took over an existing ayurvedic business in 1995, signifying a strong foundation in traditional medicine. The company has a global presence, exporting its products to countries in the Middle East and Europe, indicating a robust international market penetration. It has invested in expanding manufacturing capabilities, emphasizing a commitment to innovation and meeting increasing demand. Despite its extensive history, the absence of recent strategic updates raises questions about its current competitive positioning.

Over the past 52 weeks, Ganga Pharmaceuticals Ltd has traded between a low of ₹0.00 and a high of ₹14.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ganga Pharmaceuticals Ltd has a market capitalization of approximately 7.09. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ganga Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 100.00 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 7.09 Cr, Ganga Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ganga Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ganga Pharmaceuticals Ltd is 100.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Ganga Pharmaceuticals Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison